Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies Jasmine Foo, Franziska Michor* Computational Biology Program, Memorial Sloan-Kettering Cancer Center, New Y

First Page		Document Content
Date: 2009-11-09 09:51:16 RTT Chemotherapy Prostate cancer Drug resistance Cancer stem cell Cancer research Leukemia Cancer Breast cancer Radiation therapy Breast cancer management		Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies Jasmine Foo, Franziska Michor* Computational Biology Program, Memorial Sloan-Kettering Cancer Center, New Y Add to Reading List Source URL: michorlab.dfci.harvard.edu Download Document from Source Website File Size: 815,37 KB Share Document on Facebook

	Joint Statement on Antimicrobial Resistance Executive Summary Antimicrobial resistance, also known as AMR, is a major public health threat. The estimated burden of deaths from drug resistant infections is calc DocID: 1uNZ0 - View Document
	TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY: FINAL REPORT AND RECOMMENDATIONS THE REVIEW ON ANTIMICROBIAL RESISTANCE DocID: 1tod4 - View Document
	Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Keith P. Romano1, Akbar Ali1, William E. Royer, and Celia A. Schiffer2 Department of Biochemistry DocID: 1tlKl - View Document
	WHO/TDR TB Strain Bank New diagnostics tests for tuberculosis (TB) suitable for low-income settings are urgently needed. This includes tests for the detection of drug resistance which are of ever increasing importance as DocID: 1t8wk - View Document
	Texas A&M AgriLife ResearchSELECTED ACCOMPLISHMENTS Combating Drug Resistance DocID: 1slem - View Document